Warby Parker Inc. (WRBY) is a vertically integrated, omnichannel eyewear retailer and a U.S.-listed stock, not an ETF. Across nine attributable analyst price targets, the calculated average is approximately $29.78, which rounds to a central target of $30.
The individual targets used range from $20 at UBS to $40 at Citizens, a notably wide band. The bullish end includes Robert W. Baird at $35, Bank of America at $33, and both Piper Sandler and BTIG at $32. More cautious views include Goldman Sachs at $27, Stifel at $25, and Telsey Advisory Group at $24. Citizens raised its target to $40 from $29 on November 6, 2026, citing the November 12 Intelligent Eyewear pre-orders, Google AI advancements, and accelerating e-commerce growth.
The divergence largely comes down to how analysts weigh near-term demand softness against the company's multi-year growth initiatives. Bulls emphasize the Intelligent Eyewear launch, expanding store base, and eye-exam and insurance momentum, while more cautious analysts highlight premium valuation and uneven optical demand. The $30 figure is a calculated mean, not an official published consensus.
Shares of Warby Parker closed near $25.48 in early November 2026, with a market capitalization of roughly $3.2 billion. Reaching $30 would require a gain of about 18%, a substantial move from current levels.
The company reported third-quarter 2026 revenue of $244.7 million, up 10.4% year over year, with adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of $28.6 million, or 11.7% of revenue. Adjusted EPS of $0.04 came in below the roughly $0.09 consensus. Management narrowed full-year 2026 guidance to revenue of $966 million to $976 million and adjusted EBITDA of $117 million to $119 million.
The path toward $30 depends heavily on whether the Intelligent Eyewear launch, built with Google and Samsung, converts strong interest into revenue during 2027. Retail revenue grew 12.4% while e-commerce rose 4.8% as the Home Try-On wind-down headwind eased. Active customers grew 3% to 2.74 million, with average revenue per customer up 6.7%.
The stock's 52-week high near $31 is the most relevant resistance level, sitting just above the $30 central target. Warby Parker traded up toward that level earlier in the year before pulling back to the mid-$20s. The $30 mark therefore represents both a psychological level and a test of the prior high zone. A durable move above $31 would signal a shift in the stock's long-term structure, while a failure to hold above the mid-$20s would keep the range intact.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual analysts vary and not every report specifies an exact timeframe. Investors should monitor the November 12 Intelligent Eyewear unveiling and pricing, initial pre-order and delivery data, the February 2027 update on the combined business, and upcoming quarterly reports. Additional items include same-store sales trends, active customer growth, adjusted EBITDA margins, analyst revisions after the launch, and any commentary on production ramp and supply constraints.
AI Daily Buy/Sell Signals from Tickeron use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The system is designed to help traders discover opportunities, monitor existing positions, and identify shifting trends more efficiently than manual review alone. For investors following Warby Parker's volatile range, automated signals can offer a structured way to track momentum and turning points.
Whether Warby Parker (WRBY) can reach $30 depends on execution rather than a single catalyst. The central $30 target, the average of nine analyst price targets spanning $20 to $40, implies roughly 18% upside from the recent price near $25.48. The Intelligent Eyewear launch, margin discipline, and growth in eye exams and insurance provide a credible foundation for the bull case, while soft traffic, recent EPS misses, and a premium valuation argue for caution. The wide analyst range underscores genuine uncertainty about whether the product roadmap can re-accelerate growth. Investors should watch the launch data and analyst revisions closely, as these will shape whether the $30 target proves achievable.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, WRBY has been loosely correlated with TWST. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if WRBY jumps, then TWST could also see price increases.
| Ticker / NAME | Correlation To WRBY | 1D Price Change % | ||
|---|---|---|---|---|
| WRBY | 100% | -2.30% | ||
| TWST - WRBY | 45% Loosely correlated | +0.15% | ||
| GKOS - WRBY | 43% Loosely correlated | +2.01% | ||
| MTD - WRBY | 41% Loosely correlated | +2.57% | ||
| GMED - WRBY | 40% Loosely correlated | -12.76% | ||
| A - WRBY | 40% Loosely correlated | +1.73% | ||
More | ||||
| Ticker / NAME | Correlation To WRBY | 1D Price Change % |
|---|---|---|
| WRBY | 100% | -2.30% |
| Pharmaceuticals: Other industry (49 stocks) | 28% Poorly correlated | +2.81% |
| Pharmaceuticals industry (152 stocks) | 4% Poorly correlated | +1.60% |